Media

Press Releases


Nacuity Pharmaceuticals Logo
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the initiation of a Phase 1/2 study of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). The study, named SLO-RP, is designed to demonstrate greater retinal sensitivity in RP/USH patients treated with NPI-001 Tablets versus placebo. Read more...

Nacuity Pharmaceuticals Logo
Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute. Read more...

The Foundation Fighting Blindness logo
The Foundation Fighting Blindness, the leading charitable institution driving research to provide treatments for people affected by RP and AMD, issues a press release announcing its technical and financial support of Nacuity Pharmaceuticals.

News


The Foundation Fighting Blindness logo
This post from the The Foundation Fighting Blindness announces that Nacuity is launching a Phase 1/2 clinical trial in Australia for NPI-001, an oral treatment designed to slow vision loss in people with retinitis pigmentosa (RP) and RP associated with Usher syndrome.

The Foundation Fighting Blindness logo
Nacuity Pharmaceuticals CEO Halden Conner presented the company’s emerging drug N-Acetylcysteine Amide (NACA) at The Foundation Fighting Blindness' "Investing in Cures Summit" in Chicago, Illinois.

The Foundation Fighting Blindness logo
This post from the The Foundation Fighting Blindness' blog "Eye on the Cure" describes its investment in Nacuity Pharmaceuticals to advance RP treatment.

Publications


Neil J; Wall GM; Brown M. Antioxidant Effects of N-acetylcysteine Amide and NPI-002 on Human Skin or Equivalents. AAPS PharmSci360, Poster Abstract, October 26-November 5, 2020.

King B; Vance J; Wall GM; Shoup R. Quantitation of free and total N-acetylcysteine amide and its metabolite N-acetylcysteine in human plasma using derivatization and electrospray LC-MS/MS. J Chrom B 2019;1109:25-36.